Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients

Prostate

Volumn 67, Issue 12, 2007, Pages 1285-1292

  Kojima, Yoshiyuki ^a   Sasaki, Shoichi ^a   Shinoura, Hitomi ^b   Hayase, Masa ^a   Kubota, Yasue ^a   Hayashi, Yutaro ^a   Tsujimoto, Gozoh ^c   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

1 adrenoceptor antagonist; 1 adrenoceptor subtype; Benign prostate hyperplasia; Long term use; Therapeutic tolerance

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; NAFTOPIDIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BIOPSY; BLOTTING, WESTERN; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PIPERAZINES; PROSTATIC HYPERPLASIA; PROTEIN ISOFORMS; RECEPTORS, ADRENERGIC, ALPHA-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 34548756724     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20624     Document Type: Article

References (23)

1. Koshimizu TA, Tanoue A, Hirasawa A, Yamauchi J, Tsujimoto G. Recent advances in alphal-adrenoceptor pharmacology. Pharmacol Ther 2004;98(2):235-244.
2. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minneman KP, Ruffolo RR Jr. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: Consensus update. Pharmacol Rev 1995; 47(2):267-270.
3. Nasu K, Moriyama N, Kawabe K, Tsujimoto G, Murai M, Tanaka T, Yano J. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996;119(5):797-803.
4. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 1993;150(2 Pt 1)546-551.
5. Kojima Y, Sasaki S, Shinoura H, Hayashi Y, Tsujimoto G, Kohri K. Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate 2006;66(7):761-767.
6. Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, Gluchowski C. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha lc subtype. Mol Pharmacol 1994;45(4):703-707.
7. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004;171(3):1029-1035.
8. Grahame-Smith DG, Aronson JK. Oxford textbook of clinical pharmacology and drug therapy, 3rd edition. New York: Oxford University Press, Inc. 2002.
9. Stiles GL, Caron MG, Lefkowitz RJ. Beta-adrenergic receptors: Biochemical mechanisms of physiological regulation. Physiol Rev 1984;64(2):661-743.
10. Kenakin TP. Pharmacological analysis of drug-receptor interactions. New York: Raven 1987.
11. Yasuda K, Yamanishi T, Tojo M, Nagashima K, Akimoto S, Shimazaki J. Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: Assessment by urodynamic studies. Prostate 1994;25(1):46-52.
12. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: A randomized controlled trial. BJU Int 2005;96(4):581-586.
13. Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized crossover study. BJU Int 2006;97(4):747-751.
14. Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol 1999; 79(4):447-454.
15. Homma Y, Kawabe K, Tsukamoto T, Yamaguchi O, Okada K, Aso Y, Watanabe H, Okajima E, Kumazawa J, Yamaguchi T, Ohashi Y. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int J Urol 1996;3(4):267-273.
16. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003;170(2): 498-502.
17. Bendix Holme J, Christensen MM, Rasmussen PC, Jacobsen F, Nielsen J, Norgaard JP, Olesen S, Noer I, Wolf H, Elkjaer Husted S. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand J Urol Nephrol 1994;28(1):77-82.
18. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387- 2398.
19. de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002; 167(4):1734-1739.
20. Vincent J, Dachman W, Blaschke TF, Hoffman BB. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest 1992;90(5):1763-1768.
21. Zhang L, Taniguchi T, Tanaka T, Shinozuka K, Kunitomo M, Nishiyama M, Kamata K, Muramatsu I. Alpha-1 adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats. Br J Pharmacol 2002;135(7):1757-1764.
22. Foster HE Jr, Yono M, Shin D, Takahashi W, Pouresmail M, Afiatpour P, Latifpour J. Effects of chronic administration of doxazosin on alpha1-adrenoceptors in the rat prostate. J Urol 2004;172(6):2465-2470.
23. Yono M, Foster HE Jr, Shin D, Takahashi W, Pouresmail M, Latifpour J. Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract. Can J Physiol Pharmacol 2004;82(10):872-878.